1Newcomer JW, Second - generation (atyplcal) antipsychotics and metabolic effects: a comprehensive literature review[J]. CNS Drugs, 2005,19(Suppl 1) :1 -93.
2American Diabetes Association, American Psychiatric Association, A- merican Association of Clinical Endocrinologists, North American Association for the Study of Obesity:Consensus Development Conference on Antipsychotlc Drugs and Obesity and Diabetes[J]. Diabetes Care, 2004,27(5) :596 -601.
3Brow. S. Excess mortality of schizophrenia. A meta - analysis[J]. Br J Psychiatry, 1997,171 (4) :502 - 508.
4Angst F, Stasson HH, Clayton PJ, Angst J. Mortality of patients with mood disorders : follow - up over 34 - 38 years [ J ]. J Affect Disord, 2002,68(2 -3) :167 - 181.
5Colton CW, Manderscheid RW, Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eighe states[J]. Prey Chronic Dis 2006,3 (1) :42.
6Fontainc KR, Hero M, Harrigan EP, et al. Estimating the consequences of anti - psychotic induced weight gain on health and mortality rate[ J ]. Psychiatry Res,2001,101:277 - 288.
7Nasrallah HA, Metabolic findings From the CATIE trial and their relation to tolerability. CNS Spectr,2006,11 (7Suppl7) :32 - 39.
8Spurling RD, Lamberti JS, Olsen D, et al. Changes in metabolic parameters with switehing to aripiprazole from another second - generation antipsychotie :a retrospective chart review[J]. J Clin Psychiatry, 2007,68(3) :406 -409.
9Sikich L, Hamer RM, Bashford RA,et al. A pilot study of fispefidone, olanzapine, and haloperidol in psychotic youth : a double - blind, randomized, 8 - week trial [ J ]. Neuropsychopharmacology,2004 ;29 ( 2 ) : 133 - 145.
10Mukherjes S. High prevalence of type Ⅱ diabetes in schizophrenic patients [ J ]. Schizophrenia Research, 1995,15 (2) : 195.
